相关实验视频

Updated: Jan 18, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

甲酸IV滴滴药片对大张心肌病症小鼠的影响

Tiantian Xie¹, Dawei Wu¹

¹Jiangsu Medical College, Yancheng, China.

Drug development and industrial pharmacy

|September 10, 2025

概括

阿斯特拉加索酸IV滴滴剂 (ASDP) 改善了溶解性,并治疗小鼠的多克索鲁比诱导的扩张性心肌病 (DCM). 这些新型配方显示出显著的治疗效果,为DCM治疗提供了一个有前途的新策略.

科学领域:

药理学药理学是指药理学的学科.
心血管医学心血管医学
药物输送系统药物输送系统

背景情况:

甲酸IV (AS) 对心血管有好处,但溶解性和生物可用性差.
扩张性心肌病 (DCM) 是一种严重的心血管疾病,需要有效的治疗.
开发改进的AS配方对于其在心血管疾病中的临床应用至关重要.

研究的目的:

使用固体分散技术制备阿斯特拉加索酸IV滴液药片 (ASDP).
描述ASDP的物理化学特性,包括可溶性和溶解性.
为了评估ASDP的治疗疗效,在多克索鲁比诱导的DCM的小鼠模型中进行评估.

主要方法:

使用固体分散技术来准备和优化ASDP.
物理化学表征包括SEM,XRD,DSC,可溶性和溶解测试.
在DCM小鼠模型中,使用心声学,心脏生物标志物 (Ang II,BNP,ST2) 和组织病理学来评估治疗效果.

主要成果:

与AS.相比,ASDP表现出有利的特征,包括与AS.相比,可溶性和溶解率有所提高.
在DCM小鼠中,ASDP治疗显著缓解了心脏功能障碍,缩和亡.
在ASDP给药后,Ang II,BNP和ST2的血清水平显著降低.

结论:

ASDP有效地提高了阿斯特拉加索酸IV的可溶性和溶解.
在小鼠中,ASDP在治疗多克索鲁比诱导的扩张性心肌病症方面表现出显著的治疗疗效.
ASDP代表了治疗DCM的有希望的新配方.

关键词:

扩展性心肌病变异症扩展性心肌病变异症阿斯特拉加洛西德IV 心脏功能障碍的心脏功能障碍滴滴的药丸滴落在他们的身上.固体分散的散发方式

更多相关视频

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...